PumasAI Named Best Clinical Pharmacology Technology Development Firm in Biotechnology Awards
DOVER, Del. (May 7, 2024) - PumasAI, a science-first organization and a trailblazer in clinical pharmacology technology, has been honored as the “Best Clinical Pharmacology Technology Development Firm” at the prestigious Biotechnology Awards, hosted by Global Health & Pharma. This accolade highlights PumasAI’s significant contributions to the pharmaceutical industry through its innovative approach and dedication to enhancing life-saving decisions.
The honor is underscored by recent news highlighting the strength of the PumasAI team and its technology for the pharmaceutical industry, including:
- A pro-bono program offering modeling and simulation software to academic research institutions around the world;
- Several strategic new hires across multiple levels of the organization; and,
- A focus on leading industry workshops to further knowledge in the field, including the upcoming Scientific Modeling Augmented by Machine Learning workshop at PAGE in Rome this June.
“This recognition is a testament to the collaborative efforts with various pharmaceutical companies and research institutions. The success of PumasAI is a shared victory with these partners, driven by mutual trust and a commitment to innovation,” said Dr. Vijay Ivaturi, Co-Founder and CEO at PumasAI, and President of the International Society of Pharmacometrics (ISoP).
PumasAI offers the following:
- DeepPumas™: A pioneering scientific modeling and machine learning system tailored for healthcare data, DeepPumas™ facilitates the integration of domain-specific knowledge (such as epidemiological and pharmacological data) with data-science methodologies. This reduces reliance on large data sets and accelerates decision-making processes.
- PumasCP: A graphical user interface for managing clinical pharmacology analytics, including Non-Compartmental Analysis (NCA) and Bioequivalence (BE). PumasCP streamlines project management in these areas, offering efficiency on a fully compliant platform.
- Pumas®: Designed to meet the quantitative demands of regulatory agencies throughout the drug development cycle. Capable of performing Non-Linear Mixed Effects Modeling (NLME) using methods such as the stochastic approximation expectation maximization (SAEM), with features for Optimal Design, a leading Bayesian ecosystem, Clinical Trial Simulations, and machine and deep learning analytics.
- Lyv: A clinical decision support system that leverages individual patient history and targeted medical data for personalized patient care.
- Strategic & Scientific Consulting in the areas of Model Informed Drug Development (MIDD), novel modalities, regulatory strategy, and clinical pharmacology and pharmacometrics.
Ivaturi added, “Each scientist on staff takes pride in their work on PumasAI products and strategic consulting work to accelerate access to life-saving treatments for patients, and I am honored to see this being recognized publicly.”
To learn more about PumasAI modeling and simulation technology, visit: https://pumas.ai/our-products
About PumasAI
PumasAI is an award-winning global healthcare intelligence company with a vision to accelerate precision healthcare for patients. Proprietary software developed by the company includes the Pumas suite of products, an integrated modeling and simulation platform designed to multiply productivity across the drug development lifecycle, and Lyv, a clinical decision support system that leverages patient history and targeted medical data for personalized healthcare delivery. Scientists at PumasAI provide consulting with leading pharmaceutical innovators in clinical pharmacology, model-informed drug development (MIDD), pharmacometrics, front-end applications, and more. For additional information, visit www.pumas.ai.
